Dont be too concerned about the competitors. The Frazer DNA vaccinne is very different in approach and whilst the other 2 will be happy with a 50 or 60 % reduction in the frequency of viral outbreaks...based on animal trials we should achieve total stoppage ie 100% reduction...even if we achieve 80 or 90% it will be enough.
Gennocea so far have about 51 % reduction in shedding and Agenus. Only 15 to 34% reduction in their phase 2 trial..
Admedus and Prof Frazer are going ahead with the phase 2 trial obviously fully aware of the competitors...because the Frazer DNA vaccinne derived from the same science as GardAsil has a high probability of success.
FYI..my comments on Agenus were based on this report....
...be careful not to read viral burdens and viral shedding as the same thing....
http://www.agenusbio.com/docs/press...n-after-herpv-generated-immune-activation.php
Fox
Frazer needs to work on Ebola vax, page-11
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.00 |
Change
0.000(0.00%) |
Mkt cap ! $346.0M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.10 | $17.70 | $58.64K | 3.27K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 109 | $18.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.10 | 700 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |